Theriva announces VCN-01 Phase 1 results showing prolonged survival in refractory HNSCC

Theriva Biologics published Phase 1 clinical trial results demonstrating that VCN-01 oncolytic adenovirus combined with durvalumab produced prolonged overall survival in heavily pre-treated, immunotherapy-refractory head and neck cancer patients. The data supports VCN-01's stroma-degrading mechanism and potential to resensitize immune checkpoint inhibitor-refractory tumors, addressing a significant unmet need in this patient population.